Robust Market Growth Anticipated Throughout 2021
The global viral infections market is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8% between 2014 and 2021, reaching $117.6 billion. The expanding treatment population – driven by improved treatment options and global initiatives to improve access to treatment for many people living with chronic debilitating viral infections such as HIV – will be a key driver of this growth. Rising therapy costs, resulting from the uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are also expected to be expensive, will also promote strong market growth.
Generic Penetration Projected to Increase
Generic penetration is projected to increase considerably over the forecast period, especially in the seven major markets. The availability of generic drugs is set to increase due to a series of recent and upcoming patent expirations for key marketed products –particularly HIV. Due to enhanced cost-consciousness, clinicians will increasingly favour generic drugs over premium products in order to reduce the cost of treatment.
GBI Research’s latest report Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics, provides analysis of the global viral infections pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, with annualized market data from 2014 and forecast to 2021.
Single user price: $4,995
